Investors might want to bet on Vascular Biogenics (VBLT), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

In the annals of botched IPOs, there's the BATS disaster, and there's Facebook's notorious debut, but the train wreck that is Vascular Biogenics' IPO stands alone. The company priced its IPO on Nasdaq ...

It was the IPO that wasn't: A biotech firm hit the market and traded for six days, only to announce Friday that it wasn't issuing shares after all, thanks to a key investor's failure to follow through ...

Shares drop after management announces the pricing terms of a recently announced secondary offering. Vascular Biogenics announced that it is raising $18.75 million from the sale of 2.5 million shares ...

Vascular Biogenics (VBLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.12 per share a year ago. These figures ...

Vascular Biogenics Ltd (NASDAQ:VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec in platinum-resistant ovarian cancer did not meet ...

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new ...

The market expects Vascular Biogenics (VBLT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2021. This widely-known ...